Nippon Shinyaku : Ending March 2024(FY2023)Presentation Material for IR Meeting (1Q FY2023
August 10, 2023 at 02:09 am EDT
Share
Outline of Consolidated Financial Results for the 1st Quarter Ended June 30, 2023
August 10, 2023
NIPPON SHINYAKU CO., LTD.
1Q FY2023 Summary
◆ Revenue
◆ Operating profit ◆ Profit before tax
◆ Profit attributable to owners of parent
37,012 million yen （ + 3.9% ）
11,163 million yen （ + 8.6% ）
11,440 million yen （ + 8.8% ）
8,749 million yen （ + 6.1% ）
Revenue
Operating profit
Profit before tax
(Million yen)
Profit attributable to owners of parent
2
Segmental Review - Pharmaceuticals -
Revenues from the licensing of industrial property rights
30,407
-1,445
+2,201
-292
30,870+462
（Million yen）
1Q FY2022
1Q FY2023
YoY Change
Results
Ratio
Results
Ratio
Amt
%
Ethical drugs
20,900
68.7%
19,454
63.0%
-1,445
-6.9%
Revenues from the licensing of
6,903
22.7%
9,104
29.5%
+2,201
+31.9%
industrial property rights
Profit in co-promotion
2,603
8.6%
2,310
7.5%
-292
-11.2%
Revenue
30,407
100.0%
30,870
100.0%
+462
+1.5%
Despite the effect of price revision by MHLW* and generic products, revenue of
consolidated pharmaceuticals segment increased by 1.5% due to increase of sales of Ethical drugs such as "Viltepso" and "Uptravi", and royalty revenue from Uptravi's overseas sales.
*MHLW : Ministry of Health, Labour and Welfare 3
Segmental Review - Functional Food -
5,211
＋679
+10
＋129
＋91
＋20
6,142
＋931
（Million yen）
1Q FY2022
1Q FY2023
YoY Change
Results
Ratio
Results
Ratio
Amt
%
Protein preparations
3,605
69.2%
4,284
69.8%
+679
+18.9%
Preservatives
726
13.9%
736
12.0%
+10
+1.4%
Supplements
335
6.4%
464
7.6%
+129
+38.7%
Health food ingredients
214
4.1%
306
5.0%
+91
+42.7%
Others
330
6.4%
350
5.6%
+20
+6.2%
Revenue
5,211
100.0%
6,142
100.0%
+931
+17.9%
Revenue of consolidated functional food segment increased by 17.9% through
sales increase of Protein preparations and Supplements.
4
Operating profit
10,276
+1,393
+965
-1,173
-217
-80
11,163
-1
+887
（Million yen）
1Q FY2022
1Q FY2023
YoY Change
Results
Ratio
Results
Ratio
Amt
%
Revenue
35,619
100.0%
37,012
100.0%
+1,393
+3.9%
(Pharmaceuticals)
(30,407)
(85.4%)
(30,870)
(83.4%)
(+462)
(+1.5%)
(Functional Food)
(5,211)
(14.6%)
(6,142)
(16.6%)
(+931)
(+17.9%)
Cost of sales
13,928
39.1%
12,962
35.0%
-965
-6.9%
SG&A expenses
8,200
23.0%
8,418
22.7%
+217
+2.7%
R&D expenses
4,738
13.3%
5,911
16.0%
+1,173
+24.8%
Other income
1,652
4.6%
1,572
4.2%
-80
-4.8%
Other expenses
128
0.3%
129
0.3%
+1
+1.0%
Operating profit
10,276
28.9%
11,163
30.2%
+887
+8.6%
5
Attachments
Original Link
Original Document
Permalink
Disclaimer
Nippon Shinyaku Co. Ltd. published this content on 10 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 August 2023 06:08:03 UTC.
Nippon Shinyaku Co., Ltd. is a Japan-based company principally involved in the manufacture and sale of pharmaceutical products and functional foodstuffs. The Company operates in two business segments. The Pharmaceutical segment is involved in the manufacture and sale of urinary system therapeutic agents, blood cancer therapeutic agents, pain, inflammation and allergic therapeutic agents, digestive system therapeutic agents, cardiovascular systems and metabolic therapeutic agents. The Functional Foodstuff segment involves in the manufacture and sale of health food materials, quality stability preservatives, protein preparation, spice and seasoning products. The Company is also involved in the business support business, non-life insurance agency business, as well as the provision of real estate leasing services.
NIPPON SHINYAKU CO., LTD. 
